Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has dropped by -2.19 in relation to previous closing price of 5.94. Nevertheless, the company has seen a loss of -7.04% in its stock price over the last five trading days. globenewswire.com reported 2024-11-06 that Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
RLAY has 36-month beta value of 1.68. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLAY is 124.33M, and currently, short sellers hold a 9.69% ratio of that float. The average trading volume of RLAY on November 14, 2024 was 1.98M shares.
RLAY’s Market Performance
RLAY’s stock has seen a -7.04% decrease for the week, with a -13.80% drop in the past month and a -12.89% fall in the past quarter. The volatility ratio for the week is 5.47%, and the volatility levels for the past 30 days are at 5.74% for Relay Therapeutics Inc. The simple moving average for the past 20 days is -5.05% for RLAY’s stock, with a -21.98% simple moving average for the past 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at -13.98% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.14% of loss for the given period.
Volatility was left at 5.74%, however, over the last 30 days, the volatility rate increased by 5.47%, as shares sank -14.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.50% lower at present.
During the last 5 trading sessions, RLAY fell by -7.04%, which changed the moving average for the period of 200-days by -39.10% in comparison to the 20-day moving average, which settled at $6.12. In addition, Relay Therapeutics Inc saw -47.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Rahmer Peter, who sale 1,621 shares at the price of $6.06 back on Oct 28 ’24. After this action, Rahmer Peter now owns 390,063 shares of Relay Therapeutics Inc, valued at $9,823 using the latest closing price.
Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics Inc, sale 6,802 shares at $6.06 during a trade that took place back on Oct 28 ’24, which means that Catinazzo Thomas is holding 306,391 shares at $41,220 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -39.27 for the present operating margin
- 0.59 for the gross margin
The net margin for Relay Therapeutics Inc stands at -34.5. The total capital return value is set at -0.44. Equity return is now at value -42.69, with -37.58 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.63. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -56.63.
Currently, EBITDA for the company is -374.15 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 86.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.42.
Conclusion
To put it simply, Relay Therapeutics Inc (RLAY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
